GENE ONLINE|News &
Opinion
Blog

2021-06-23| Asia-PacificFunding

China’s Qitan Technology Raises Over RMB400 Million in Series B Funding to Develop Nanopore Gene Sequencing

by Kathy Huang
Share To

Tan Hsieh, Co-founder of Qitan Technology (Image Source: QitanTech)

On June 8th, Qitan Technology, a China-based gene sequencing company, announced the completion of a Series B round funding for more than RMB400 million, co-led by GL Ventures and CDH Investments. Other participating investors include BioTrack Capital, Huagai Capital, and Sunshine Insurance Group’s Riverhead Capital.

Prior to this round, Qitan Technology had completed a series A funding round in May 2020, with a total financing amount of over RMB100 million. Four months later, Qitan successfully launched its fourth-generation gene sequencer, QNome-9604.

 

China’s Upstream Company in Nanopore Gene Sequencing

Since its inception in 2016, Qitan Technology has focused on developing gene sequencing techniques. In September 2020, it launched QNome-9604, which is China’s first self-developed fourth-generation nanopore single-molecule gene sequencer.

Unlike traditional DNA sequencers, QNome-9604 operates without a PCR process, and the technical improvement makes it low-cost yet remains high performance. Application areas of this portable sequencer include clinical research, public health detection, and judicial identification. 

 

Use of the Funding

After completing this round of financing, Qitan Technology plans to develop its fourth-generation gene sequencing offerings and expand its R&D technology. The new product is expected to go to market this year. 

The huge amount of funding will also be used to scale up the team and improve the products for larger gene sequencing markets. According to statistics, the Chinese market for DNA sequencing will grow to $2.9 billion by 2022, and Qitan Technology has seized the opportunity.

Related Article: HitGen Partners with Dorian to develop DNA-Encoded Library-Based Anti-Aging Drugs

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
China Blocks Illumina’s Sequencers as U.S. Tariffs Double–Trade War Fallout Intensifies
2025-03-06
R&D
Revolutionary Sequencing Technique for Cancer Signature Detection
2023-07-11
Pfizer-backed Flare Taps Caris To Boost Precision Oncology Pipeline
2023-04-17
LATEST
AI-Based Model Accurately Classifies Pediatric Sarcomas Using Digital Pathology Images
2025-04-30
Taiwan’s BPIPO and DCB Join Japan’s LINK-J and FIRM for First Regenerative Medicine Investment Forum in Tokyo
2025-04-29
Study Shows ctDNA Liquid Biopsy Detects Colorectal Cancer Recurrence Earlier Than Imaging
2025-04-29
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top